A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

GSK's candidate influenza vaccine 1562902A

Intramuscular dose on Day 0 and Day 21

BIOLOGICAL

FluarixTM

Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule

BIOLOGICAL

Placebo

Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule

Trial Locations (1)

80810-050

GSK Investigational Site, Curitiba/Paraná

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00866580 - A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine | Biotech Hunter | Biotech Hunter